Genome-Wide Association Study Identifies Novel Colony Stimulating Factor 1 Locus Conferring Susceptibility to Cryptococcosis in Human Immunodeficiency Virus-Infected South Africans. by Kannambath, Shichina et al.
Ac
ce
pte
d M
an
us
cri
pt
 
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society 
of America. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution 
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
Genome-wide association study identifies novel CSF1 locus conferring susceptibility to 
cryptococcosis in HIV-infected South Africans  
Shichina Kannambath1,2, Joseph N. Jarvis3,4, Rachel M Wake1,5, Nicky Longley1, Angela Loyse1, Vicky 
Matzaraki6, Raúl Aguirre-Gamboa6, Cisca Wijmenga6, Ronan Doyle3, Maria Paximadis7, Caroline T. 
Tiemessen7, Vinod Kumar6,9, Alan Pittman1, Graeme Meintjes8, Thomas S. Harrison1,5,8, Mihai G. 
Netea9,10 & Tihana Bicanic1,5* 
1Institute of Infection and Immunity, St. George’s University of London, 2National Institute of Health 
Research Biomedical Research Centre at Guy's and St Thomas' Hospital and King's College London, 
London, UK, 3Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London 
School of Hygiene & Tropical Medicine, London, 4Botswana Harvard AIDS Institute Partnership, 
Gaborone, Botswana,5Clinical Infection, St George’s Hospital NHS Trust , 6University of Groningen, 
University Medical Center Groningen, Department of Genetics, Groningen, the Netherlands ,7Centre 
for HIV and STIs, National Institute for Communicable Diseases and Faculty of Health Sciences, 
University of the Witwatersrand, Johannesburg, South Africa, 8Department of Medicine and 
Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and 
Molecular Medicine, University of Cape Town,  9Department of Internal Medicine and Radboud 
Center for Infectious Diseases, Radboud University, the Netherlands, 10Department for Genomics & 
Immunoregulation, Life and Medical Sciences Institute (LIMES), University of Bonn, Germany 
 
Corresponding author: tbicanic@sgul.ac.uk tel +44 20 87252911 
Alternate corresponding author: shichina.kannambath@kcl.ac.uk tel +44 20 7188 5745 
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/advance-article/doi/10.1093/ofid/ofaa489/5925041 by guest on 19 O
ctober 2020
Ac
ce
pte
d M
an
us
cri
pt
 
2 
 
Abstract  
Background. Cryptococcus is the most common cause of meningitis in HIV-infected Africans. Despite 
universal exposure, only 5-10% of patients with HIV/AIDS and profound CD4+ T-cell depletion 
develop disseminated cryptococcosis: host genetic factors may play a role. Prior targeted 
immunogenetic studies in cryptococcosis have comprised few Africans. 
Methods. We analysed genome-wide SNP genotype data from 524 patients of African descent:  243 
cases (advanced HIV with cryptococcal antigenemia and/or cryptococcal meningitis) and 281 
controls (advanced HIV, no history of cryptococcosis, negative serum cryptococcal antigen)  
Results. Six loci upstream of the colony stimulating factor 1 (CSF1) gene, encoding macrophage 
colony-stimulating factor (M-CSF), were associated with susceptibility to cryptococcosis at p<10-6, 
and remained significantly associated in a second South African cohort (83 cases; 128 controls). 
Meta-analysis of the genotyped CSF1 SNP rs1999713 showed an OR for cryptococcosis susceptibility 
of 0.53 (95% CI 0.42-0.66, p=5.96x10-8). Ex vivo functional validation and transcriptomic studies 
confirmed the importance of macrophage activation by M-CSF in host defence against Cryptococcus 
in HIV-infected patients and healthy, ethnically-matched controls. 
Conclusion. This first genome-wide association study of susceptibility to cryptococcosis has 
identified novel and immunologically relevant susceptibility loci, which may help define novel 
strategies for prevention or immunotherapy of HIV-associated cryptococcal meningitis. 
 
Key words: Genome-wide association study (GWAS); Infectious Disease; Cryptococcal meningitis; 
Cryptococcus; HIV; South Africa; Africa; macrophage colony stimulating factor (M-CSF); CSF1 
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Background  
The fungus Cryptococcus is a common cause of meningitis in people living with HIV/AIDS and 
responsible for 15% of all-AIDS related deaths globally [1]. Despite antiretroviral therapy (ART) 
rollout, the incidence of cryptococcal meningitis (CM) remains high in Africa, estimated at ~200,000 
cases annually[1]. In Africa, outcomes of current therapy are poor, with acute mortality of 25-40% 
even with optimised therapy within a randomised multi-centre trial[2], and 70% in ‘real world’ 
settings[3].  
Exposure to Cryptococcus, an environmental saprophyte, is universal via inhalation. A population 
seroprevalence survey in the USA showed anti-cryptococcal antibodies are common[4]. 
Disseminated cryptococcal infection, manifesting as meningoencephalitis, usually occurs in 
individuals with depressed cell-mediated immunity, typically presenting as an opportunistic infection 
in advanced HIV (CD4 T-cell count<100/µL). Despite likely exposure, not all patients with advanced 
HIV develop disseminated cryptococcosis: prevalence of cryptococcal antigenemia (CRAG), 
representing early dissemination from the lungs, is around 6% in this population[1]. Following 
treatment of both cryptococcosis and underlying HIV, despite comparable CD4 counts,  CRAG-
positive individuals have a 12-month mortality rate around three times greater than CRAG-negative 
controls[5], suggesting that additional host immune factors, beyond that reflected by the CD4 count, 
may contribute to cryptococcosis susceptibility. 
Host immunity to Cryptococcus neoformans, an intracellular pathogen, requires co-ordinated innate 
and adaptive responses, with phagocytosis by classically-activated (M1) macrophages promoting 
robust Th1-type responses and the production of pro-inflammatory cytokines (TNF-α and IFN-γ) 
playing a central role in fungal clearance and host survival[3,6]. In apparently immunocompetent 
hosts, a number of CM susceptibility determinants have been described, including idiopathic CD4 
lymphopenia, antibodies to GM-CSF and IFN-γ and Fc-γ receptor and mannose-binding lectin 
polymorphisms[3,7,8]. 
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Prior immunogenetic studies performed in CM have studied candidate genes in small populations 
(n=100-150) comprising few African individuals [3,7–9]. In the only CM genetic susceptibility study in 
HIV-positive patients, targeted sequencing of the Fc-γ receptor in a cohort of 164 predominantly 
Caucasian men (55 HIV-positive with CM; 54 HIV-positive and 55 HIV-negative controls without CM), 
demonstrated that individuals homozygous for the Fc-γR3A 158V polymorphism had 20-fold 
increased odds of developing CM[9]. Despite Sub-Saharan Africa having a high infectious disease 
burden, few genome-wide association studies (GWAS) of infectious disease susceptibility have been 
conducted in people of African descent: published studies include tuberculosis[10] and 
malaria[11,12]. Specific challenges to GWAS in the African population include higher genetic 
diversity, low linkage disequilibrium, and more complex genetic structure[13],though in the long-
term these aspects can be exploited for fine-mapping of association signals. 
Here, we report on the first GWAS of genetic susceptibility to cryptococcosis in an HIV-infected 
population, using DNA from a discovery cohort of 524 cases and controls of African descent 
recruited in Cape Town 2005-14 and a validation cohort of 211 recruited in Johannesburg 2015-17.  
Methods  
Human cohorts  
Discovery and validation cohort: For the discovery cohort, 243 cases were recruited as part of four 
clinical trials (one observational, three randomised) of HIV-associated CM and a cryptococcal 
antigenemia study in ART-naïve adults conducted in Cape Town, South Africa 2005-2014[14–18]. 
Cases had disseminated cryptococcal infection and/or cryptococcal meningitis as confirmed by 
positive serum and/or CSF cryptococcal antigen and/or CSF culture. 281 controls were recruited 
contemporaneously at the same hospital and referring clinic as the cases, had no history of 
cryptococcal disease and a negative serum cryptococcal antigen. All cases and controls were HIV-
positive adults (age>18) with nadir CD4 cell count<100/μL who were ART-naïve or within 3 months 
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of starting ART. The validation cohort included 63 cases and 128 controls with CD4 cell count<100/μL 
recruited as part of a cryptococcal antigen screening study in ART-naïve HIV-infected adults in 2015-
17[19](Table 1). Twenty cases from a clinical trial of HIV-CM in Kwazulu-Natal were also included in 
this cohort[16]. 
Cryptococus-specific transcriptome and functional characterisation cohort: RNA-seq was 
performed on PBMCs from healthy volunteers of self-identified Xhosa ethnicity recruited in Cape 
Town. The functional characterisation cohort included 5 HIV-infected patients of diverse ethnicities 
recruited at St George’s Hospital, London, with CD4 count <200 cells/μl and not on ART within <12 
months. Healthy donor PBMCs used were obtained from leukocyte cones. 
Patient consent statement. The studies were approved by ethics committees at the University of 
Cape Town, the University of Witswatersrand, and the London School of Hygiene of Tropical 
Medicine. All participants gave written informed consent. 
Further details of experimental methods and computational analyses are provided in the 
Supplementary methods.  
Genotyping and association analyses  
524 cases and controls from the discovery cohort were genotyped using the Illumina 
HumanOmniExpressExome-8 v1.0 SNP chip, an exome-based array with >700,000 genome-wide 
markers and >240,000 exonic markers. 211 samples from the validation cohort were genotyped on 
the Illumina GSA beadchip GSA MD v1. Samples with a low call rate (≤ 99%) and variants with a 
Hardy–Weinberg equilibrium (HWE)≤ 0.00001, call rate < 0.99, missingness test (GENO > 0.01) and 
minor allele frequency (MAF) < 0.001 were excluded from further analyses.  Eleven genetically 
divergent samples were excluded from the discovery cohort and six from the validation cohort. A 
total of 245091 variants from 513 discovery samples passed quality control and were analysed. 
Variants were aligned to the 1000 Genome reference and the data was imputed using the Michigan 
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Imputation server. Post-imputation QC were used to remove low-quality (r2 <= 0.8) imputed variants 
before further analyses.  
The association analysis was performed and genetic susceptibility to disseminated cryptococcosis 
tested using logistic regression. p value distribution was assessed using a Quantile-Quantile (Q-Q) 
plot and there was no inflation effect on the association analysis. Discovery and validation cohort 
imputed datasets were subsequently merged and a combined cohort association analysis was 
performed on 2,686,126 variants, with the significance threshold set at p<5x10-6. The impact of top 
SNPs on gene expression was explored using eQTL information from the HaploReg and Genotype 
Tissue Expression (GTex) databases (see Online Methods).Information on SNP association with 
annotated genes and variants within 500kb of each SNP was collated. Genes associated with SNPs 
with p<5x10-3 were included in pathway enrichment and gene ontology analyses. At the CSF1 locus, 
SNP rs1999713 was hard-called on both genotyping platforms for both cohorts so we performed a 
meta-analysis of the discovery and validation cohorts to negate any uncertainty from imputation, 
using an allele and fixed effects model as the effect size and direction was very similar in both the 
discovery and replication cohorts.  
M-CSF functional characterisation experiments 
PBMCs from HIV-infected patients (n=5) and healthy volunteers were pre-treated with M-CSF or 
anti-MCSF antibody and co-cultured with Cryptococcus neoformans H99 (serotype A reference 
strain) for 24h. Cells were lysed, plated onto fresh SAB agar for 48h and Colony forming units (CFU) 
counted. For the phagocytosis assays, PBMCs were pre-treated as above and then challenged with 
pre-labelled heat-killed C neoformans for 24h at 370C. Cells were then captured on a flow cytometer 
and the percentage of cells with internalised cryptococcus identified.  
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RNA sequencing and analyses 
PBMCs were stimulated with heat-killed C neoformans (MOI 0.1) for 24h. RNA was extracted and a 
sequencing library prepared and sequenced as described in supplementary methods. Following 
quality control measures, reads were mapped to the human reference genome (hg19). Reads were 
annotated and differentially-expressed genes between controls and Cn-treated samples identified. 
Genes with significant differential expression were used in gene ontology and pathway analyses. 
Results  
 
Genome-wide association analysis  
We performed a GWAS of Cryptococcus susceptibility in a discovery cohort of 524 age-, gender-, and 
CD4 count-matched South African HIV-infected patients: cases with disseminated cryptococcosis 
(defined as positive serum CRAG and/or CM, n=243) and controls (n=281) with no cryptococcosis. 
The validation cohort comprised 83 cases and 128 controls of African descent (Table 1). After 
imputation and quality-control measures (Supplementary Fig. 1a), ~9.2 million variants from 240 
cases and 273 controls (discovery) and 79 cases and 126 controls (validation) were analysed using 
regression analysis.  
In the discovery cohort, we identified multiple loci associated with susceptibility to cryptococcosis 
(Fig. 1a). Although no individual SNP passed the genome-wide significance threshold p<5x10-8, we 
identified 49 SNPs with p<10-5 associated with cryptococcosis (Table 2). Six of the top susceptibility 
SNPs (p<7.54 x 10-6; OR 0.49-0.53) were located within 2.5 kb upstream of the CSF1 gene encoding 
macrophage colony stimulating factor, M-CSF (Fig. 1b), a cytokine promoting macrophage activation 
and phagocytosis.  The top associated SNP rs1999714 (OR=0.49, p=8.39x10-7) was located in the 
block of linkage disequilibrium (LD) of ~2.5 kb, defined by significant r2> 0.5 LD of surrounding SNPs 
with rs1999714) close to the CSF1 gene (Fig. 1b). Another top variant, rs12124202 (OR=0.53, 
p=7.54x10-6) was in the gene enhancer region (position GRCh38.p12 chr1: 109,905,601-109,906,901, 
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GeneHancer id GH01J109905) and other SNPs (including rs1999714) were all close to the CSF1 
regulatory region. However, exploring the impact of these candidate SNPs on gene on gene 
regulation using a number of databases (Online Methods) revealed no expression quantitative traits 
for any of the CSF1 SNPs, including the SNP in the enhancer region of CSF1.  Other susceptibility 
SNPs of potential relevance to Cryptococcus-macrophage interactions included rs6768912 (OR 1.8, 
p=7.56x10-6) in the intronic region of NCEH1 (neutral cholesterol ester hydrolase) and rs7213159 (OR 
1.9, p=9.79x10-6), a non-coding transcript variant of CSNK1D (casein kinase I). NCEH1 encodes 
neutral cholesterol ester hydrolase, an enzyme removing cholesterol, which plays a pivotal role in 
antiviral responses (including to HIV), in macrophages[20]. Gene silencing of the CSNK1D gene has 
been shown to significantly reduce intracellular mycobacterial load in murine macrophages[21] 
(Table 2). 
To validate findings from our discovery cohort, we performed GWAS in a separate South African 
cohort of 79 cases and 126 controls.  The CSF1 SNPs were independently significant in this smaller 
cohort (OR 0.52-0.63, p<0.05, Table 3).  In the combined cohort of 319 cases and 399 controls, all six 
CSF1 SNPs remained significantly associated with cryptococcosis susceptibility (Table 3, Fig. 1c-d, 
Supplementary Fig. 2). A meta-analysis of the (non-imputed)  genotyped CSF1 SNP rs1999713 
(present in both discovery and validation cohorts) using a fixed effects allele model generated an OR 
of 0.53 (95% CI 0.42-0.66, p=5.96x10-8; heterogeneity, I2 =0%, p =0.8539 in the combined cohort (Fig. 
2).  
Transcriptomics in healthy PBMCs and overlap with GWAS findings  
Using PBMCs from six healthy donors of self-identified Xhosa ethnicity, we performed RNA-seq 
following stimulation with heat-killed C neoformans for 24h. Compared to unstimulated PBMCs, 653 
genes were significantly up- or down-regulated (fold change >2; adj value <0.05, Supplementary 
Table 1). CSF1 was significantly upregulated (log2-fold change 2.55, adjusted p=2.6x10-16) along with 
IFN-γ, TNFα, CCL1 and CCL8 (Supplementary Table 1). Looking for an overlap between genes 
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differentially expressed in the RNA-seq experiment and genes associated with significant SNPs 
(p<1x10-3) in the GWAS, we found 38 common genes (Table 4): 9 of which, including CSF1, were 
significantly up-regulated upon cryptococcal stimulation. Genes common to GWAS and RNA-seq 
were associated with functions such as cell adhesion (CD36, CSF1, NRG1 and TGFBI), macrophage 
differentiation (CSF1, IL31RA), cell proliferation (RASGRF1, CSF1, NRG1, SPOCK1 and TGFBI) and ion 
transport (ATP6V0D2, CACNA2D3, CTTNBP2, KCNJ6, SLC8A1 and SLCO2B1).  
Gene ontology analysis of differentially expressed genes in healthy controls identified enrichment of 
cytokine activity, phagocytosis, complement and T-cell proliferation (Supplementary Table 2). 
Pathway analysis of these genes identified enrichment of cytokine-cytokine receptor interaction, 
complement and coagulation cascades and Toll-like signalling pathways (Supplementary Table 2).  
These findings lend further support to the importance of genes involving macrophage activation, 
differentiation and phagocytosis, including CSF1, to Cryptococcal immune responses in the South 
African population.  
 
Functional characterisation in PBMCs from patients with advanced HIV 
To further examine the importance of M-CSF in cryptococcal phagocytosis and killing, we performed 
ex vivo experiments using PBMCs of five HIV-infected patients (ART-naïve, CD4 count<200 cells/uL). 
Exogenous M-CSF significantly improved cryptococcal phagocytosis and killing by HIV-infected 
PBMCs (Fig. 3). When M-CSF receptors were blocked with specific antibodies, phagocytosis and 
fungal killing were similar to that of unstimulated PBMCs, suggesting either incomplete receptor 
block or absence of endogenous M-CSF production in patients (Fig. 3).  
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Discussion   
Despite bearing the largest infectious disease burden, African individuals are under-represented in 
studies of disease susceptibility[22]. Globally, fungal infections pose a major threat to human health 
as a result of the expansion of immunosuppressive interventions and the ongoing HIV epidemic [23]. 
Due to the challenges in recruiting large enough cohorts, the first GWAS in an invasive fungal 
infection (candidaemia) was published in 2014[24]. The present study is the first to be conducted for 
cryptococcosis, taking 12 years (2005-2017) to enroll a total of 735 patients. 
 
Unlike prior targeted sequencing approaches, we took an unbiased, hypothesis-generating approach 
as used previously for candidemia[24,25], combining GWAS in a clearly defined case-control cohort, 
backed up by validation in a second cohort, transcriptomics in ethnically-matched healthy controls 
and functional studies. Whilst no individual locus reached genome-wide significance, meta-analysis 
of the non-imputed genotyped CSF1 SNP rs1999713 demonstrated p<10-8 (OR 0.53; 95% CI 0.42-
0.66, p=5.96X10-8) and was independently significant in both our discovery and validation cohorts. 
Notably, this result was obtained in an African population, in whom GWAS power is limited by 
extensive genetic diversity and low linkage disequilibrium[13]. 
 
Whilst no SNPs identified lay within coding regions, we identified immunologically plausible 
upstream genetic variants with potential regulatory roles, notably 5 SNPs in the regulatory region 
and one SNP on the enhancer region of the CSF1 gene encoding M-CSF. M-CSF induces survival, 
proliferation, chemotaxis, differentiation, and activation of monocytes/macrophages, including 
microglia[26,27]. All six SNPs were confirmed in the validation cohort, remaining significantly 
associated with risk of cryptococcosis in the combined cohort. Although we did not have CSF1 
genotype data for the healthy controls to link with gene expression, CSF1 was also one of the most 
highly up-regulated genes upon cryptococcal stimulation of PBMCs from healthy, ethnically-matched 
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volunteers, and experiments confirmed the importance of M-CSF in uptake and killing of 
Cryptococcus by PBMCs from HIV-infected patients. 
 
Exogenous M-CSF enhances the anti-cryptococcal activity of human monocyte-derived macrophages 
and enhanced cryptococcal killing in a murine model, and was synergistic with fluconazole[28–30]. 
M-CSF is one of the principal regulators of macrophage function[27,31], acting as a potent 
proliferation signal, increasing blood and tissue macrophage numbers[31–33]. M-CSF-primed 
macrophages are typically more phagocytic and less competent at antigen presentation, primed to 
M2 stimuli[32]; however, M-CSF does not induce a full M2 phenotype, with M-CSF primed 
macrophages able to respond to a variety of pro-inflammatory stimuli including IFN- and toll-like 
receptor activation[31,32,34,35]. M-CSF acts synergistically with IFN- to drive pro-inflammatory 
chemokine production including CCL2 (MCP-1)[31], and is expressed in subset of T-cells that also 
express Th1 markers[36]. T-cell derived M-CSF has been shown to play a crucial role in the control of 
blood-borne intracellular pathogens[36] and blocking M-CSF increases susceptibility to intracellular 
infections with Listeria and Mycobacterium tuberculosis[37,38].  The exact role of M-CSF in 
protective anti-cryptococcal immune responses in the context of HIV co-infection is unclear, 
although extensive data demonstrating the importance of effective alveolar macrophage responses 
in controlling early cryptococcal infection[6], and the key role of circulating and tissue 
macrophage/microglial responses during later disseminated disease[39][40], provide a plausible 
basis for why variations in CSF1 gene expression might impact susceptibility to cryptococcal disease. 
Of interest, the genotyped CSF1 SNP rs1999713 is common in different populations, with sampled 
African populations having the lowest minor allele frequency (MAF) of 0.31 - comparable to 0.34 
found in our control group- with East Asian populations having the highest MAF at 
0.68(https://gnomad.broadinstitute.org/). 
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Searching for inherited immune defects in anti-cryptococcal responses in the context of profound 
acquired CD4 T-cell depletion might seem paradoxical: yet given only a minority of patients with 
advanced HIV develop disseminated cryptococcosis despite presumed ubiquitous exposure, such an 
approach has the potential to highlight the contribution of other factors, including the central role of 
macrophage phagocytosis and killing[41]... Macrophages are also infected by HIV and act as its tissue 
reservoir[42,43] and are involved in trafficking both pathogens to the CNS. We postulate that, in the 
setting of HIV-cryptococcal co-infection, genotypes rendering macrophages more permissive to 
uptake and intracellular survival of intracellular pathogens are likely to confer susceptibility to 
disseminated cryptococcosis; either through direct effects on cryptococcal intracellular burden, or 
indirectly through an impact on HIV burden[44]. FcγR polymorphisms identified in prior targeted 
sequencing studies [8,9] could exert an impact through either increasing phagocyte cargo (via 
increased binding and uptake of C. neoformans–immune complexes), shown to be associated with 
CSF fungal burden in HIV-CM[41], and/or increased immune activation via ADCC, leading to 
disruption of the blood brain barrier or CNS tissue injury[9]. Both M-CSF and the M-CSF receptor 
have been proposed as targets in the treatment of HIV neurodegenerative disease[45,46], and M-
CSF treatments for invasive fungal infections have been investigated in animal models[47,48] and 
early stage clinical trials[49]. 
 
Our study had several limitations. The relatively small sample size limited our statistical power and 
genotype arrays differed for the two cohorts. The discovery cohort was genotyped on a chip biased 
towards European populations, whilst the validation cohort was typed using the newly available 
global screening array (containing multi-ethnic genome-wide content), making imputation crucial for 
analysis of the combined cohort. Better designed genotyping chips representing African genetic 
diversity (such as the GSA array and newer arrays under development) will mean less reliance on 
Imputation methods to fill in the gaps in the African genomes. We lacked genotype data on the 
healthy volunteers that would have allowed us to examine effects of CSF1 genotype on cytokine 
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expression upon cryptococcal stimulation. Furthermore, there was a paucity of eQTL data from 
African populations on the impact of the upstream variants identified on CSF1 gene expression and 
M-CSF production: this could be explored in future studies using PBMCs of genotyped individuals.  
Beyond host genotype, other unaccounted for factors, such as those associated with environmental 
cryptococcal exposure, or concurrent opportunistic infections, may have impacted on cryptococcosis 
susceptibility. 
 
In any GWAS of infectious disease susceptibility, pathogen variation is an additional and usually 
unaccounted for element[13]. The completion of large multi-site African phase III trials in HIV-
associated cryptococcal meningitis provides the opportunity to undertake a larger pan-African GWAS 
of disease severity and treatment response, developing bioinformatic approaches to integrate host 
and pathogen genomics with host CSF immune profiling and pathogen virulence phenotyping to 
determine host and pathogen factors underlying poor clinical outcome[2,50]. 
 
In summary, we have identified and replicated a novel cryptococcosis susceptibility factor in HIV-
infected Africans, the importance of which was further confirmed through ex vivo functional 
immune studies in patients with advanced HIV as well as healthy, ethnically-matched controls. Our 
findings demonstrate that small but well-defined GWAS can identify novel and immunologically 
relevant susceptibility loci for an important cause of mortality in an African population, provided 
they are replicated and complemented by functional approaches. Identifying a high-risk genotype 
helps elucidate disease mechanism and has the potential to identify novel strategies for targeted 
prevention and host-directed immunotherapy.   
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/advance-article/doi/10.1093/ofid/ofaa489/5925041 by guest on 19 O
ctober 2020
Ac
ce
pte
d M
an
us
cri
pt
 
14 
 
Funding  
This work was supported by the Wellcome Trust Strategic Award for Medical Mycology and Fungal 
Immunology (grant number 097377/Z/11/Z) awarded to TB and MN. JNJ is funded by the National 
Institute for Health Research (NIHR) using additional Official Development Assistance (ODA) funding 
as a Research Professor (Ref RP-2017-08-ST2-012). The views expressed are those of the author(s) 
and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. MGN 
was supported by a Spinoza Grant of the Netherlands Organization for Scientific Research and an 
ERC Advanced Grant (#833247). VK is funded by Radboud University Medical Center Hypatia Tenure 
Track Grant, and a Research Grant (2017) from the European Society of Clinical Microbiology and 
Infectious Diseases (ESCMID). RW was supported by a grant from the Meningitis Research 
Foundation. The validation cohort study was in part funded by the South African Chairs Initiative of 
the Department of Science and Innovation and National research Foundation of South Africa 
(awarded to CTT). GM was supported by the Wellcome Trust (098316 and 203135/Z/16/Z), the 
South African Research Chairs Initiative of the Department of Science and Technology and National 
Research Foundation (NRF) of South Africa (Grant No 64787), and NRF incentive funding (UID: 
85858).  
 
Acknowledgements  
We thank all the patients and volunteers who participated in the study; research nurses 
Nomqondiso Sidibana and Zomzi Williams  who helped with genetics consent for the studies; the 
Johannesburg study team who helped with recruitment of patients in the validation cohort; Thobile 
Tracey Shabangu for technical assistance in the validation cohort team; the UCT study co-ordinator 
Rene Goliath, nurses at Site C Khayelitsha who organised recruitment for the transcriptome study; 
Professor Robert Wilkinson, University of Cape Town, in whose laboratory the transcriptome 
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/advance-article/doi/10.1093/ofid/ofaa489/5925041 by guest on 19 O
ctober 2020
Ac
ce
pte
d M
an
us
cri
pt
 
15 
 
experiments were conducted; and Professor Derek Macallan at St George’s University of London 
who provided assistance with the M-CSF PBMC stimulation experiments.  
 
Conflict of interest 
TB has received Speaking fees from Gilead Sciences and Pfizer and research funding from Gilead 
Sciences unrelated to the submitted work. All other authors have declared that no conflict of 
interest exists. 
 
Availability of data and materials 
The human SNP array summary datasets and raw RNAseq data supporting the conclusions of this 
article are available on figshare through this link https://figshare.com/s/b953f3192c77cef0be98 The 
software and detailed analyses steps we undertook are detailed here 
https://github.com/alanmichaelpittman100/Crypto-GWAS 
 
Author Contributions   
TB, TSH and MN conceived and designed the research. TB, JNJ, RW, NL, AL and GM enrolled patients 
and collected samples in the clinical trials and genetics sub-studies. SK performed the 
transcriptomics study. SK, MP and CT undertook the DNA extractions. SK, VM, RA, CW, VK, RD and 
AP performed the genomic analyses. SK and TB interpreted the data. SK, JNJ and TB wrote the paper, 
with input from all the authors.  
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/advance-article/doi/10.1093/ofid/ofaa489/5925041 by guest on 19 O
ctober 2020
Ac
ce
pte
d M
an
us
cri
pt
 
16 
 
Corresponding author/ request for reprints: 
Tihana Bicanic 
Institute of Infection and Immunity 
St George’s University of London 
London SW17 0RE 
United Kingdom 
 
Tel +44 (0) 2087252911 
Email: tbicanic@sgul.ac.uk 
 
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/advance-article/doi/10.1093/ofid/ofaa489/5925041 by guest on 19 O
ctober 2020
Ac
ce
pte
d M
an
us
cri
pt
 
17 
 
References  
1.  Rajasingham R, Smith RM, Park BJ, et al. Global burden of disease of HIV-associated 
cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017; 17(8):873–881.  
2.  Molloy SF, Kanyama C, Heyderman RS, et al. Antifungal Combinations for Treatment of 
Cryptococcal Meningitis in Africa. N Engl J Med. 2018; 378(11):1004–1017.  
3.  Williamson PR, Jarvis JN, Panackal AA, et al. Cryptococcal meningitis: Epidemiology, 
immunology, diagnosis and therapy. Nat. Rev. Neurol. 2016. p. 13–24.  
4.  Goldman DL, Khine H, Abadi J, et al. Serologic evidence for Cryptococcus neoformans 
infection in early childhood. Pediatrics. 2001; 107(5):E66.  
5.  Mfinanga S, Chanda D, Kivuyo SL, et al. Cryptococcal meningitis screening and community-
based early adherence support in people with advanced HIV infection starting antiretroviral 
therapy in Tanzania and Zambia: An open-label, randomised controlled trial. Lancet. 2015; 
385(9983):2173–2182.  
6.  Tenforde MW, Scriven JE, Harrison TS, Jarvis JN. Immune correlates of HIV-associated 
cryptococcal meningitis. PLoS Pathog. 2017.  
7.  Hu XP, Wu JQ, Zhu LP, et al. Association of Fcγ receptor IIB polymorphism with cryptococcal 
meningitis in HIV-uninfected chinese patients. PLoS One. 2012; 7(8):1–6.  
8.  Ou XT, Wu JQ, Zhu LP, et al. Genotypes coding for mannose-binding lectin deficiency 
correlated with cryptococcal meningitis in HIV-uninfected Chinese patients. J Infect Dis. 2011; 
203(11):1686–1691.  
9.  Rohatgi S, Gohil S, Kuniholm MH, et al. Fc gamma receptor 3A polymorphism and risk for HIV-
associated cryptococcal disease. MBio. 2013; 4(5).  
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/advance-article/doi/10.1093/ofid/ofaa489/5925041 by guest on 19 O
ctober 2020
Ac
ce
pte
d M
an
us
cri
pt
 
18 
 
10.  Thye T, Vannberg FO, Wong SH, et al. Genome-wide association analyses identifies a 
susceptibility locus for tuberculosis on chromosome 18q11.2. Nat Genet. 2010; 42(9):739–
741.  
11.  Jallow M, Teo YY, Small KS, et al. Genome-wide and fine-resolution association analysis of 
malaria in West Africa. Nat Genet. 2009; 41(6):657–665.  
12.  Timmann C, Thye T, Vens M, et al. Genome-wide association study indicates two novel 
resistance loci for severe malaria. Nature. 2012; 489(7416):443–446.  
13.  Chapman SJ, Hill A V. Human genetic susceptibility to infectious disease. Nat Rev Genet. 
2012; 13(3):175–188.  
14.  Bicanic T, Meintjes G, Wood R, et al. Fungal Burden, Early Fungicidal Activity, and Outcome in 
Cryptococcal Meningitis in Antiretroviral-Naive or Antiretroviral-Experienced Patients Treated 
with Amphotericin B or Fluconazole. Clin Infect Dis. 2007; 45(1):76–80.  
15.  Jarvis JN, Meintjes G, Rebe K, et al. Adjunctive interferon-γ immunotherapy for the treatment 
of HIV-associated cryptococcal meningitis: A randomized controlled trial. AIDS. 2012; 
26(9):1105–1113.  
16.  Loyse A, Wilson D, Meintjes G, et al. Comparison of the early fungicidal activity of high-dose 
fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with 
amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis. 
2012; 54(1):121–128.  
17.  Longley N, Jarvis JN, Meintjes G, et al. Cryptococcal Antigen Screening in Patients Initiating 
ART in South Africa: A Prospective Cohort Study. Clin Infect Dis. 2016; 62(5):581–587.  
18.  Bicanic T, Wood R, Meintjes G, et al. High‐Dose Amphotericin B with Flucytosine for the 
Treatment of Cryptococcal Meningitis in HIV‐Infected Patients: A Randomized Trial. Clin Infect 
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/advance-article/doi/10.1093/ofid/ofaa489/5925041 by guest on 19 O
ctober 2020
Ac
ce
pte
d M
an
us
cri
pt
 
19 
 
Dis. 2008; .  
19.  Wake RM, Govender NP, Omar T, et al. Cryptococcal-related Mortality Despite Fluconazole 
Preemptive Treatment in a Cryptococcal Antigen Screen-and-Treat Program. Clin Infect Dis. 
2019; .  
20.  Bukrinsky M, Sviridov D. Human immunodeficiency virus infection and macrophage 
cholesterol metabolism. J Leukoc Biol. 2006; 80(5):1044–1051.  
21.  Jayaswal S, Kamal MA, Dua R, et al. Identification of Host-Dependent Survival Factors for 
Intracellular Mycobacterium tuberculosis through an siRNA Screen. PLoS Pathog. 2010; 
6(4):e1000839.  
22.  S.J. C, A.V.S. H. Human genetic susceptibility to infectious disease. Nat Rev Genet. 2012; 
13(3):175–188.  
23.  Brown GD, Denning DW, Levitz SM. Tackling human fungal infections. Science (80- ). 2012; 
336(6082):647.  
24.  Kumar V, Cheng S-C, Johnson MD, et al. Immunochip SNP array identifies novel genetic 
variants conferring susceptibility to candidaemia. Nat Commun. Nature Publishing Group; 
2014; 5:4675.  
25.  Smeekens SP, Ng A, Kumar V, et al. Functional genomics identifies type i interferon pathway 
as central for host defense against Candida albicans. Nat Commun. 2013; 4.  
26.  Smith AM, Gibbons HM, Oldfield RL, et al. M-CSF increases proliferation and phagocytosis 
while modulating receptor and transcription factor expression in adult human microglia. J 
Neuroinflammation. Journal of Neuroinflammation; 2013; 10(1):1.  
27.  Endele M, Loeffler D, Kokkaliaris KD, et al. CSF-1-induced Src signaling can instruct monocytic 
lineage choice. Blood. 2017; .  
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/advance-article/doi/10.1093/ofid/ofaa489/5925041 by guest on 19 O
ctober 2020
Ac
ce
pte
d M
an
us
cri
pt
 
20 
 
28.  Nassar F, Brummer E, Stevens DA. Effect of in vivo macrophage colony-stimulating factor on 
fungistasis of bronchoalveolar and peritoneal macrophages against Cryptococcus 
neoformans. Antimicrob Agents Chemother. 1994; 38(9):2162–2164.  
29.  Brummer E, Stevens DA. Macrophage colony-stimulating factor induction of enhanced 
macrophage anticryptococcal activity: Synergy with fluconazole for killing. J Infect Dis. 1994; 
170(1):173–179.  
30.  Brummer E, Gilmore GL, Shadduck RK, Stevens DA. Development of macrophage 
anticryptococcal activity in vitro is dependent on endogenous M-CSF. Cell Immunol. 1998; .  
31.  Tagliani E, Shi C, Nancy P, Tay CS, Pamer EG, Erlebacher A. Coordinate regulation of tissue 
macrophage and dendritic cell population dynamics by CSF-1. J Exp Med. 2011; .  
32.  Jenkins SJ, Ruckerl D, Thomas GD, et al. IL-4 directly sig als tissue-resident macrophages to 
proliferate beyond homeostatic levels controlled by CSF-1. J Exp Med. 2013; .  
33.  Lin WY, Xu D, Austin CD, et al. Function of CSF1 and IL34 in Macrophage Homeostasis, 
Inflammation, and Cancer. Front Immunol. 2019; .  
34.  Rodriguez RM, Suarez-Alvarez B, Lavín JL, et al. Signal Integration and Transcriptional 
Regulation of the Inflammatory Response Mediated by the GM-/M-CSF Signaling Axis in 
Human Monocytes. Cell Rep. 2019; 29(4):860–872.e5.  
35.  Hume DA, MacDonald KPA. Therapeutic applications of macrophage colony-stimulating 
factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood. 2012.  
36.  Fontana MF, Melo GL de, Anidi C, et al. Macrophage Colony Stimulating Factor Derived from 
CD4+T Cells Contributes to Control of a Blood-Borne Infection. PLoS Pathog. 2016; .  
37.  Jin Y, Dons L, Kristensson K, Rottenberg ME. Colony-Stimulating Factor 1-Dependent Cells 
Protect against Systemic Infection with Listeria monocytogenes but Facilitate Neuroinvasion. 
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/advance-article/doi/10.1093/ofid/ofaa489/5925041 by guest on 19 O
ctober 2020
Ac
ce
pte
d M
an
us
cri
pt
 
21 
 
Infect Immun. 2002; 70(8):4682–4686.  
38.  Higgins DM, Sanchez-Campillo J, Rosas-Taraco AG, et al.  Relative Levels of M-CSF and GM-
CSF Influence the Specific Generation of Macrophage Populations during Infection with 
Mycobacterium tuberculosis . J Immunol. 2008; .  
39.  Jarvis JN, Meintjes G, Bicanic T, et al. Cerebrospinal Fluid Cytokine Profiles Predict Risk of 
Early Mortality and Immune Reconstitution Inflammatory Syndrome in HIV-Associated 
Cryptococcal Meningitis. PLoS Pathog. 2015; 11(4):1–17.  
40.  Scriven JE, Graham LM, Schutz C, et al. The CSF Immune Response in HIV-1-Associated 
Cryptococcal Meningitis: Macrophage Activation, Correlates of Disease Severity, and Effect of 
Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2017; 75(3):299–307.  
41.  Sabiiti W, Robertson E, Beale MA, et al. Efficient phagocytosis and laccase activity affect the 
outcome of HIV-associated cryptococcosis. 2014; 124(5).  
42.  Wong ME, Jaworowski A, Hearps AC. The HIV reservoir in monocytes and macrophages. 
Front. Immunol. 2019.  
43.  Merino KM, Allers C, Didier ES, Kuroda MJ. Role of monocyte/macrophages during HIV/SIV 
infection in adult and pediatric acquired immune deficiency syndrome. Front. Immunol. 2017.  
44.  Swingler S, Mann AM, Zhou J, Swingler C, Stevenson M. Apoptotic killing of HIV-1-infected 
macrophages is subverted by the viral envelope glycoprotein. PLoS Pathog. 2007; .  
45.  Haine V, Fischer-Smith T, Rappaport J. Macrophage colony-stimulating factor in the 
pathogenesis of HIV infection: potential target for therapeutic intervention. J Neuroimmune 
Pharmacol. 2006; 1(1):32–40.  
46.  Rovida E, Sbarba P Dello. Colony-Stimulating Factor-1 Receptor in the Polarization of 
Macrophages: A Target for Turning Bad to Good Ones? J Clin Cell Immunol. 2015; 06(06).  
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/advance-article/doi/10.1093/ofid/ofaa489/5925041 by guest on 19 O
ctober 2020
Ac
ce
pte
d M
an
us
cri
pt
 
22 
 
47.  Cenci E, Bartocci A, Puccetti P, Mocci S, Stanley ER, Bistoni F. Macrophage colony-stimulating 
factor in murine candidiasis: Serum and tissue levels during infection and protective effect of 
exogenous administration. Infect Immun. 1991; .  
48.  Hume DA, Denkins Y. The deleterious effect of macrophage colony-stimulating factor (CSF-1) 
on the pathology of experimental candidiasis in mice. Lymphokine Cytokine Res. 1992; .  
49.  Nemunaitis J, Shannon-Dorcy K, Appelbaum FR, et al. Long-term follow-up of patients with 
invasive fungal disease who received adjunctive therapy with recombinant human 
macrophage colony-stimulating factor. Blood. 1993; .  
50.  Molefi M, Chofle AA, Molloy SF, et al. AMBITION-cm: Intermittent high dose AmBisome on a 
high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan 
Africa: Study protocol for a randomized controlled trial. Trials. 2015; .  
  
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/advance-article/doi/10.1093/ofid/ofaa489/5925041 by guest on 19 O
ctober 2020
Ac
ce
pte
d M
an
us
cri
pt
 
23 
 
Figure legends 
Fig 1.  Manhattan plot and regional association plots for Discovery cohort GWAS. a) Manhattan plot 
showing the genome-wide p values of association with CM. The y axis represents the log10 P values of SNPs 
and their chromosomal positions are shown on the x axis. The horizontal blue line shows the significance 
threshold of p<1x10-4. P-values were obtained by logistic regression. 6 SNPs upstream of the CSF1 gene on 
chr1 lay above this threshold, including a SNP at the enhancer region of CSF1 b) Regional association plots 
at the Chr1 associated with CSF1 genes. Estimated recombination rates are shown in blue to reflect the 
local LD structure around the associated top SNP and its correlated proxies (with bright red indicating 
highly correlated and pale red indicating weakly correlated. c) Manhattan plot showing the genome-wide p 
values of association with cryptococcosis. The y axis represents the log10 p values of SNPs and their 
chromosomal positions are shown on the x axis. The horizontal blue line shows the significance threshold 
of p<1x10-5. The p-values were obtained though linear models (lrt) in GEMMA software with 15 ancestry 
principal components as covariates. d) Regional association plots at the Chr1 CSF1 gene locus. 
Fig 2. Meta-analysis and Forest plot of hard-called genotyped CSF1 SNP rs1999713, present in both 
discovery and validation cohorts. Model shown is allele test under a fixed effects model (heterogeneity, I2 
=0%, p =0.8539). The presence of rs1999713 was associated with an OR of 0.53 (95% CI 0.42-0.66, 
p=5.96x10-8) for development of cryptococcosis in the combined cohort. 
Fig 3. Cryptococcus internalisation and killing by PBMCs from patients with advanced HIV infection (n=5).  
PBMCs were pre-treated to block MCSF receptors using α-MCSF or provided with additional MCSF and then 
co-infected with heat-killed cryptococcus. a) PBMCs from HIV-infected patients showed significantly higher 
internalisation of Cryptococcus when treated with additional MCSF. b) HIV-infected patient PBMCs also 
exhibit better killing of Cryptococcus compared to the non-treated PBMCs. Phagocytosis and fungal killing 
in anti-MCSF treated samples were similar to controls suggesting incomplete receptor block or lack of 
endogenous MCSF production in patients. For the 5 patients, there were 2 technical replicates for the 
phagocytosis experiments and three for the fungal killing experiments: all data points are shown on the 
graph. p values shown using two-sided t test; box and whiskers plot shows median ± IQR.  
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Table 1.  Age, sex and CD4 count for Cases and Controls in Discovery and Validation cohorts. Median 
(range) shown for continuous variables. 
 
Discovery Cohort Controls Cases 
n 218 243 
Age 33(18-66) 33(18-62) 
Sex (% F) 66% 61% 
CD4(cell/uL) 46(23-78) 37(16-67) 
   Validation Cohort Controls Cases 
n 128 83 
Age  40 (18-76) 39(21-68) 
Sex (% F) 56% 54% 
CD4(cell/uL) 44(1-99) 25(1-90) 
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Table 2: List of variants (p<1.0x10-5) associated with cryptococcosis (CC) in Discovery cohort 
CH
R 
BP SNP Closest gene Gene region  
Minor/Maj
or 
Frequency 
Cases/Contr
ol 
P 
value 
OR 
1 
11045003
3 
rs1999714 CSF1 
Upstream gene 
variant 
T/G 0.21/0.35 
8.4E-
07 
0.5
0 
  
11044808
0 
rs12121374 CSF1 
Upstream gene 
variant 
C/T 0.23/0.36 3E-06 
0.5
2 
  
11044996
2 
rs1999715 CSF1 
Upstream gene 
variant 
A/C 0.24/0.37 3E-06 
0.5
3 
  
11045017
7 
rs1999713 CSF1 
Upstream gene 
variant 
C/T 0.24/0.37 
4.1E-
06 
0.5
3 
  
11044859
0 
rs12124202 CSF1 Enhancer A/G 0.23/0.35 
7.5E-
06 
0.5
3 
  
21004881
9 
rs2064163 DIEXF 
Upstream gene 
variant 
G/T 0.28/0.42 
4.8E-
06 
0.5
5 
2 788370 rs4854383 AC113607.1 intronic G/C 0.32/0.20 
6.5E-
06 
1.9
2 
  74452327 rs12476235 
RP11-
287D1.3 
intronic A/G 0.26/0.15 
8.4E-
06 
2.0
3 
  74454448 rs60003281 
RP11-
287D1.3 
intronic C/G 0.26/0.15 
9.7E-
06 
2.0
1 
3 
17237853
6 
rs6768912 NCEH1 intronic A/C 0.5/0.36 
7.6E-
06 
1.7
8 
4 
18221424
7 
rs6846320 
RP11-
665C14.2 
Upstream gene 
variant 
A/C 0.21/0.10 
8.2E-
07 
2.4
0 
5 78878938 rs12514204 PAPD4 
Upstream gene 
variant 
C/G 0.51/0.36 
2.2E-
06 
1.8
3 
  78881151 rs72635607 PAPD4 
Upstream gene 
variant 
T/C 0.17/0.29 
5.9E-
06 
0.5
0 
  78896859 rs72635609 PAPD4 
Upstream gene 
variant 
T/G 0.17/0.29 
7.5E-
06 
0.5
1 
  78064511 rs10079201 LHFPL2 
Upstream gene 
variant 
A/G 0.16/0.28 
9.1E-
06 
0.5
1 
7 
13387698
5 
rs2068375 LRGUK intronic T/C 0.03/0.10 
6.1E-
06 
0.2
8 
  
15772654
8 
rs11150898
3 
PTPRN2 intronic G/A 0.12/0.04 
8.4E-
06 
3.0
0 
  
13388551
2 
rs4732006 LRGUK intronic G/A 0.03/0.10 
9.8E-
06 
0.2
9 
  
13388872
6 
rs78496580 LRGUK intronic A/G 0.03/0.10 
9.8E-
06 
0.2
9 
  
13388897
9 
rs79956644 LRGUK intronic A/C 0.03/0.10 
9.8E-
06 
0.2
9 
  
13389105
9 
rs76591747 LRGUK intronic T/G 0.03/0.10 
9.8E-
06 
0.2
9 
  
13389559
2 
rs77103757 LRGUK intronic T/C 0.03/0.10 
9.8E-
06 
0.2
9 
8 567740 rs1703893 ERICH1 
Upstream gene 
variant 
G/A 0.12/0.22 
6.7E-
06 
0.4
6 
9 92263074 rs78649414 GADD45G intronic C/G 0.07/0.16 
5.7E-
06 
0.3
9 
  92258429 rs7025202 GADD45G intronic G/A 0.10/0.20 
6.3E-
06 
0.4
4 
  80978737 rs73651328 PSAT1 
Upstream gene 
variant 
G/A 0.06/0.15 
7.3E-
06 
0.3
8 
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  92263407 rs74398964 GADD45G intronic T/C 0.07/0.16 
8.4E-
06 
0.4
0 
  92261102 rs80245985 GADD45G intronic T/C 0.08/0.17 
9.9E-
06 
0.4
2 
13 
10850420
8 
rs1396593 FAM155A intronic A/G 0.10/0.03 
2.3E-
06 
3.7
0 
  
10850514
1 
rs9520606 FAM155A intronic T/A 0.10/0.03 
2.3E-
06 
3.7
0 
  
10850637
5 
rs2136266 FAM155A intronic T/C 0.10/0.03 
2.3E-
06 
3.7
0 
  51950848 rs79789954 INTS6 intronic T/C 0.08/0.17 
2.9E-
06 
0.4
0 
  
10850386
9 
rs9520603 FAM155A intronic A/G 0.10/0.03 
3.3E-
06 
3.4
8 
  
10850399
5 
rs9520605 FAM155A intronic C/T 0.12/0.04 
3.4E-
06 
3.1
2 
  85474990 rs9602571 
RP11-
531P20.1 
Upstream gene 
variant 
A/G 0.09/0.19 
3.8E-
06 
0.4
2 
  85475371 rs9602572 
RP11-
531P20.1 
Upstream gene 
variant 
G/C 0.09/0.19 
3.8E-
06 
0.4
2 
  60084350 
rs18765773
6 
RNU7-88P 
Upstream gene 
variant 
T/G 0.10/0.03 
3.8E-
06 
3.6
2 
14 34930846 rs74046057 SPTSSA intronic T/C 0.53/0.39 
4.8E-
06 
1.7
8 
  34930523 rs57186368 SPTSSA intronic T/C 0.53/0.39 
6.5E-
06 
1.7
7 
  34928860 rs12434081 SPTSSA intronic G/A 0.53/0.39 
8.7E-
06 
1.7
6 
16 85146454 rs75842988 FAM92B 
Upstream gene 
variant 
A/G 0.24/0.12 
2.9E-
06 
2.2
0 
17 5568721 
rs11547009
7 
NLRP1 
Upstream gene 
variant 
G/A 0.18/0.07 
1.1E-
06 
2.6
4 
  5568733 
rs11154161
0 
NLRP1 
Upstream gene 
variant 
C/T 0.19/0.09 
3.7E-
06 
2.3
7 
  80223048 rs7213159 CSNK1D intronic C/T 0.32/0.20 
9.8E-
06 
1.8
9 
18 8211568 
rs11251456
4 
PTPRM intronic C/T 0.11/0.03 
4.5E-
06 
3.3
5 
  29586237 rs12454708 RNF125 
Upstream gene 
variant 
C/G 0.03/0.10 
6.1E-
06 
0.2
8 
  52320409 rs11877451 C18orf26 
Upstream gene 
variant 
G/A 0.17/0.28 
9.7E-
06 
0.5
1 
  52322820 rs7233418 C18orf26 
Upstream gene 
variant 
G/C 0.17/0.28 
9.7E-
06 
0.5
1 
20 49810845 rs78757036 AL035457.1 
Upstream gene 
variant 
A/G 0.08/0.17 
5.9E-
06 
0.4
1 
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Table 3: List of variants (p<1.0x10-5) associated with cryptococcosis (CC) in combined GWAS (Discovery and Validation) cohort 
   
Combined Cohort  
      
Discovery Cohort 
   
Replication series 
  
CHR BP SNP Closest gene Gene region Minor/Major 
Frequency 
Case/Control 
P value OR 
 
Frequency Case/Control P value OR 
 
Frequency Case/Control P value OR 
1 110450033 rs1999714 CSF1 Upstream gene variant T/G 0.2401/0.3219 2.62E-07 0.6656 
 
0.2104/0.3553 3.112E-07 0.4835 
 
0.178/0.2817 0.03136 0.5519 
1 110449962 rs1999715 CSF1 Upstream gene variant A/C 0.2616/0.3342 4.55E-07 0.7059 
 
0.2333/0.3755 8.836E-07 0.5063 
 
0.1949/0.3175 0.01424 0.5205 
1 110451118 rs7535558 CSF1 Upstream gene variant C/T 0.3146/0.3808 6.66E-07 0.7461 
 
0.2958/0.4304 8.153E-06 0.556 
 
0.2627/0.381 0.02558 0.579 
1 110450177 rs1999713 CSF1 Upstream gene variant C/T 0.2649/0.3354 7.90E-07 0.7141 
 
0.2333/0.3736 1.193E-06 0.5102 
 
0.2119/0.3175 0.03575 0.578 
10 91937740 rs4933565 LINC01375 Upstream gene variant T/G 0.2715/0.1855 1.11E-06 1.637 
 
n/a n/a n/a 
 
0.3305/0.2183 0.0208 1.768 
10 91937734 rs4933564 LINC01375 Upstream gene variant T/A 0.2715/0.1855 1.14E-06 1.637 
 
n/a n/a n/a 
 
0.3305/0.2183 0.0208 1.768 
1 110448590 rs12124202 CSF1 Enhancer A/G 0.2500/0.3256 1.83E-06 0.6906 
 
0.2188/0.3553 1.563E-06 0.508 
 
0.1949/0.2897 0.0526 0.5937 
1 110448080 rs12121374 CSF1 Upstream gene variant T/C 0.2566/0.3256 2.54E-06 0.7152 
 
0.2188/0.3608 6.303E-07 0.496 
 
0.2119/0.2976 0.08344 0.6344 
15 68182254 rs28445794 RNU6-1 Upstream gene variant C/T 0.1887/0.2002 3.69E-06 0.9292 
 
0.1229/0.2216 3.364E-05 0.4922 
 
0.1949/0.2778 0.08681 0.6295 
15 68180746 rs34743389 RNU6-1 Upstream gene variant A/G 0.1904/0.2064 4.90E-06 0.9043 
 
0.1271/0.2253 0.000043 0.5007 
 
0.1949/0.2817 0.07376 0.6172 
6 29833057 rs3128900 HLA-H intronic T/G 0.1755/0.1806 4.97E-06 0.9658 
 
0.2417/0.1557 0.0005349 1.728 
 
0.1525/0.131 0.5745 1.195 
15 68180471 rs62014301 RNU6-1 Upstream gene variant A/G 0.1904/0.2064 5.05E-06 0.9043 
 
0.1271/0.2253 0.000043 0.5007 
 
0.1949/0.2817 0.07376 0.6172 
5 78638719 rs114228467 JMY, HOMER1 Upstream gene variant A/G 0.0464/0.0147 7.39E-06 3.249 
 
n/a n/a n/a 
 
0.0593/0.0079 0.002787 7.883 
5 78635829 rs148260321 JMY, HOMER1 Upstream gene variant G/C 0.0464/0.0147 7.78E-06 3.249 
 
n/a n/a n/a 
 
0.0593/0.0079 0.002787 7.883 
6 52162415 rs61126502 MCM3, IL17F Upstream gene variant T/C 0.0431/0.0405 8.06E-06 1.065 
 
n/a n/a n/a 
 
0.0254/0.0952 0.01611 0.2478 
9 81835737 rs273465 LOC101927450 Upstream gene variant A/C 0.154/0.1671 8.13E-06 0.9073 
 
0.1042/0.2015 1.817E-05 0.4609 
 
0.1356/0.1905 0.1933 0.6667 
6 29943688 rs2394251 HLA-H intronic C/G 0.2566/0.317 9.32E-06 0.7439 
 
n/a n/a n/a 
 
0.2712/0.2063 0.1653 1.431 
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Table 4: List of GWAS- identified genes (variants with p<0.001) showing differential expression in the RNA-
seq experiment (differential log2 fold change >1). The top 9 genes, including CSF1, were significantly 
upregulated in response to Cryptococcal stimulation of PBMCs from healthy Xhosa volunteers.  
Common Genes 
Number of variants 
(p<1.0x10-3 ) 
log2 Fold Change padj 
IL31RA 3 3.65 2.5E-26 
CSF1 8 2.55 2.6E-16 
BCL2L14 2 1.90 3.5E-08 
CCL24 1 1.59 0.00242 
DPF3 13 1.06 0.02754 
SAMD4A 7 1.48 2.8E-05 
NDRG2 1 1.41 8.8E-06 
HPSE2 2 1.27 0.04782 
RASGRF1 1 1.18 0.00489 
CD36 2 -1.01 0.03026 
C10orf54 2 -1.02 0.00183 
NAV1 1 -1.05 0.01309 
NAV2 49 -1.06 0.01309 
GPR141 1 -1.11 0.02783 
INSR 1 -1.21 0.0072 
MUC16 1 -1.21 0.0015 
HRASLS5 4 -1.27 0.03434 
PCSK5 6 -1.27 0.03238 
ABCA13 9 -1.28 0.00193 
SLC47A1 1 -1.34 0.04405 
PXDN 4 -1.35 0.0147 
EEPD1 1 -1.40 0.00358 
NHSL1 1 -1.43 0.00021 
ATP6V0D2 1 -1.46 0.00209 
SLC8A1 3 -1.47 0.01127 
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SPOCK1 2 -1.51 0.00183 
EPB41L3 1 -1.54 0.01091 
KCNJ6 1 -1.61 6.6E-10 
SLCO2B1 1 -1.69 0.00552 
NRG1 2 -1.74 0.0002 
CTTNBP2 3 -1.82 0.00173 
TGFBI 1 -1.97 0.00059 
GLIS3 1 -2.03 6E-06 
CACNA2D3 1 -2.08 3.6E-06 
NCEH1 3 -2.11 6.5E-05 
DLEU7 2 -2.20 1E-08 
LTBP2 1 -2.47 4.2E-09 
PID1 4 -3.06 1.1E-08 
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